N-GLYCOSYLATED INSULIN ANALOGUES

摘要

Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1_9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1 _4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(j. 4)GlcNAc(1_4)Man3GlcNAe2; or selected from N-glycans in the group consisting of ????(?_ 4)Gal(1 _4)GlcN Ac(1_4)Man3 GlcN Ac2-